Company patents

Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts

Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts demonstrates a strong and growing focus on core pharma-biotech areas, with "Pharmaceutical Preparations" representing over half of its portfolio (52.4%) and experiencing significant growth of 88.9% in 2025. Surprisingly, while maintaining a strong presence in traditional biotech, the organization also shows an emerging interest in "Material & Chemical Analysis," which saw a remarkable 200.0% year-over-year growth in 2025, suggesting a diversification into analytical methods beyond pure biological applications, although patent filings across most categories show a sharp decline so far in 2026.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

63 US filings (since 2023) · 9 categories · 19 themes

Advanced Biomarker Detection Assays

Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.

Material & Chemical Analysis
Who else files here? →
29since 2023
+200.0%YoY
Antibody Engineering & Therapeutics

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Peptides & ProteinsPharmaceutical PreparationsTherapeutic Activity (Pharma)Material & Chemical Analysis
Who else files here? →
18since 2023
+233.3%YoY
Immunomodulatory Protein Design

Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.

Peptides & Proteins
Who else files here? →
17since 2023
+133.3%YoY
Advanced Cell & Gene Therapies

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Pharmaceutical PreparationsPeptides & Proteins
Who else files here? →
15since 2023
0.0%YoY
Molecular Biomarkers for Disease

Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.

Genetic & Microbiological Assays
Who else files here? →
14since 2023
+133.3%YoY
Clinical Diagnostics & Prognostics

Computational methods and systems for analyzing biological data (e.g., genomic, proteomic, clinical) to diagnose diseases, predict patient prognosis, assess treatment response, or stratify patients for therapy.

Bioinformatics
Who else files here? →
9since 2023
+150.0%YoY
Immune Checkpoint Modulation

Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.

Therapeutic Activity (Pharma)
Who else files here? →
9since 2023
-80.0%YoY
Cellular Immunotherapy

Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.

Therapeutic Activity (Pharma)
Who else files here? →
7since 2023
+100.0%YoY
Recombinant Protein & Peptide Therapeutics

Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.

Therapeutic Activity (Pharma)
Who else files here? →
3since 2023
new
Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Pharmaceutical Preparations
Who else files here? →
3since 2023
0.0%YoY
Targeted Drug Formulation Delivery

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Pharmaceutical Preparations
Who else files here? →
3since 2023
0.0%YoY
Surgical Imaging & Navigation

Systems and methods that use imaging technologies, computer vision, and augmented reality to provide real-time guidance, localization, and visualization during surgical procedures or for detailed anatomical assessment.

Medical Diagnostics & Surgery
Who else files here? →
3since 2023
new
Nucleic Acid-Based Therapies

Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.

Therapeutic Activity (Pharma)Pharmaceutical Preparations
Who else files here? →
3since 2023
n/a
Protein & Peptide Engineering

Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.

Peptides & Proteins
Who else files here? →
1since 2023
new
Advanced Genomic Sequence Analysis

Computational techniques and algorithms for processing, aligning, and interpreting raw biological sequence data (DNA, RNA, protein), including identifying genetic variations, classifying organisms, or predicting sequence attributes.

Bioinformatics
Who else files here? →
1since 2023
new
Integrated Molecular Diagnostic Systems

Self-contained or modular devices designed to automate and integrate multiple steps of molecular diagnostic assays, from sample preparation to result interpretation, often for point-of-care or high-throughput applications.

Genetic & Microbiological Assays
Who else files here? →
1since 2023
new
Physiological Monitoring & Diagnostics

Systems and methods for non-invasive or minimally invasive collection and analysis of physiological data (e.g., blood pressure, electrolytes, genetic markers, B cell repertoire) to assess patient health status, screen for conditions, or aid in diagnosis.

Healthcare Informatics
Who else files here? →
1since 2023
new
Interventional & Implantable Therapies

Design and application of devices that are inserted into the body or implanted to treat diseases, modulate physiological functions, or repair anatomical structures.

Medical Diagnostics & Surgery
Who else files here? →
1since 2023
n/a
Video Enhancement & Object Tracking

Methods and systems for improving the quality of video streams, generating intermediate frames, or continuously locating and following objects within a sequence of images, even under occlusion.

Image Processing
Who else files here? →
1since 2023
n/a

Patents

Showing 1-10 of 84

Page 1 of 9
US 20260102474 A1APPLICATION
A61K38/48

MODIFIED ACE2 PROTEINS WITH IMPROVED ACTIVITY AGAINST SARS-COV-2

Filed:2023-09-27Pub:2026-04-16
Applicant:Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts

The present invention relates to therapeutic proteins and medical uses thereof. The present invention relates to modified ACE2 protein having increased binding affinity for the SARS-COV-2 spike protein compared to wildtype ACE2 protein, wherein said modified ACE2 protein is lacking enzymatic activity and is fused to (i) a modified Fc domain of human immunoglobulin, wherein the Fc domain has either enhanced immunostimulating activity (Fc + ) or attenuated immunostimulating activity (Fc − ) or (ii) a protein that specifically binds to T cells or further enhances immunostimulating activity. The invention also relates to a polynucleotide encoding the modified ACE2 protein of the present invention, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide or the vector or expression construct, and a non-human transgenic organism comprising the polynucleotide or the vector or expression construct. Moreover, the present invention relates also to a method for the manufacture of a modified ACE protein according to the present invention and to a medicament comprising the modified ACE2 protein, the polynucleotide or the vector or expression construct of the invention. Furthermore, the invention relates to medical uses of the modified ACE2 protein, the polynucleotide or the vector or expression construct in treating and/or preventing a disease or disorder associated with SARS-COV-2 infection. Finally, the invention provides a kit comprising the modified ACE2 protein, the polynucleotide or the vector or expression construct of the invention.